So far, it lacks a medical certification but includes important glioma molecular markers, such as pathogenic DNA sequence alterations in IDH1, IDH2, BRAF, CDKN2A, PTEN, NOTCH1, and TP53. This evidence concerns the gene BRAF and central nervous system cancer.